共查询到20条相似文献,搜索用时 390 毫秒
1.
Nazila V. Jafari Sarah A. Kuehne Clare E. Bryant Mamoun Elawad Brendan W. Wren Nigel P. Minton Elaine Allan Mona Bajaj-Elliott 《PloS one》2013,8(7)
Clostridium difficile infection (CDI) is the leading cause of hospital and community-acquired antibiotic-associated diarrhoea and currently represents a significant health burden. Although the role and contribution of C. difficile toxins to disease pathogenesis is being increasingly understood, at present other facets of C. difficile-host interactions, in particular, bacterial-driven effects on host immunity remain less studied. Using an ex-vivo model of infection, we report that the human gastrointestinal mucosa elicits a rapid and significant cytokine response to C. difficile. Marked increase in IFN-γ with modest increase in IL-22 and IL-17A was noted. Significant increase in IL-8 suggested potential for neutrophil influx while presence of IL-12, IL-23, IL-1β and IL-6 was indicative of a cytokine milieu that may modulate subsequent T cell immunity. Majority of C. difficile-driven effects on murine bone-marrow-derived dendritic cell (BMDC) activation were toxin-independent; the toxins were however responsible for BMDC inflammasome activation. In contrast, human monocyte-derived DCs (mDCs) released IL-1β even in the absence of toxins suggesting host-specific mediation. Infected DC-T cell crosstalk revealed the ability of and 630 WT strains to elicit a differential DC IL-12 family cytokine milieu which culminated in significantly greater Th1 immunity in response to R20291. Interestingly, both strains induced a similar Th17 response. Elicitation of mucosal IFN-γ/IL-17A and Th1/Th17 immunity to C. difficile indicates a central role for this dual cytokine axis in establishing antimicrobial immunity to CDI. R20291相似文献
2.
F. Christopher Peritore-Galve John A. Shupe Rory J. Cave Kevin O. Childress M. Kay Washington Sarah A. Kuehne D. Borden Lacy 《PLoS pathogens》2022,18(2)
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea and pseudomembranous colitis in the USA. In addition to these symptoms, patients with CDI can develop severe inflammation and tissue damage, resulting in life-threatening toxic megacolon. CDI is mediated by two large homologous protein toxins, TcdA and TcdB, that bind and hijack receptors to enter host cells where they use glucosyltransferase (GT) enzymes to inactivate Rho family GTPases. GT-dependent intoxication elicits cytopathic changes, cytokine production, and apoptosis. At higher concentrations TcdB induces GT-independent necrosis in cells and tissue by stimulating production of reactive oxygen species via recruitment of the NADPH oxidase complex. Although GT-independent necrosis has been observed in vitro, the relevance of this mechanism during CDI has remained an outstanding question in the field. In this study we generated novel C. difficile toxin mutants in the hypervirulent BI/NAP1/PCR-ribotype 027 strain to test the hypothesis that GT-independent epithelial damage occurs during CDI. Using the mouse model of CDI, we observed that epithelial damage occurs through a GT-independent process that does not involve immune cell influx. The GT-activity of either toxin was sufficient to cause severe edema and inflammation, yet GT activity of both toxins was necessary to produce severe watery diarrhea. These results demonstrate that both TcdA and TcdB contribute to disease pathogenesis when present. Further, while inactivating GT activity of C. difficile toxins may suppress diarrhea and deleterious GT-dependent immune responses, the potential of severe GT-independent epithelial damage merits consideration when developing toxin-based therapeutics against CDI. R20291相似文献
3.
4.
Lisa F. Dawson Esmeralda Valiente Alexandra Faulds-Pain Elizabeth H. Donahue Brendan W. Wren 《PloS one》2012,7(12)
Clostridium difficile is a Gram-positive anaerobic, spore-forming bacillus that is the leading cause of nosocomial diarrhoea worldwide. We demonstrate that C. difficile aggregates and forms biofilms in vitro on abiotic surfaces. These polymicrobial aggregates are attached to each other and to an abiotic surface by an extracellular polymeric substance (EPS). The EPS matrix provides the scaffold bonding together vegetative cells and spores, as well as forming a protective barrier for vegetative cells against oxygen stress. The master regulator of sporulation, Spo0A, may play a key role in biofilm formation, as genetic inactivation of spo0A in strain exhibits decreased biofilm formation. Our findings highlight an important attribute of C. difficile pathogenesis, which may have significant implications for infection, treatment and relapse. R20291相似文献
5.
The LexA regulated SOS network is a bacterial response to DNA damage of metabolic or environmental origin. In Clostridium difficile, a nosocomial pathogen causing a range of intestinal diseases, the in-silico deduced LexA network included the core SOS genes involved in the DNA repair and genes involved in various other biological functions that vary among different ribotypes. Here we describe the construction and characterization of a lexA ClosTron mutant in C. difficile strain. The mutation of lexA caused inhibition of cell division resulting in a filamentous phenotype. The lexA mutant also showed decreased sporulation, a reduction in swimming motility, greater sensitivity to metronidazole, and increased biofilm formation. Changes in the regulation of toxin A, but not toxin B, were observed in the lexA mutant in the presence of sub-inhibitory concentrations of levofloxacin. C. difficile LexA is, therefore, not only a regulator of DNA damage but also controls many biological functions associated with virulence. R20291相似文献
6.
7.
Background
Clostridium difficile is the leading cause of hospital-associated diarrhoea in the US and Europe. Recently the incidence of C. difficile-associated disease has risen dramatically and concomitantly with the emergence of ‘hypervirulent’ strains associated with more severe disease and increased mortality. C. difficile contains numerous mobile genetic elements, resulting in the potential for a highly plastic genome. In the first sequenced strain, 630, there is one proven conjugative transposon (CTn), Tn5397, and six putative CTns (CTn1, CTn2 and CTn4-7), of which, CTn4 and CTn5 were capable of excision. In the second sequenced strain, , two further CTns were described. R20291Results
CTn1, CTn2 CTn4, CTn5 and CTn7 were shown to excise from the genome of strain 630 and transfer to strain CD37. A putative CTn from , misleadingly termed a phage island previously, was shown to excise and to contain three putative mobilisable transposons, one of which was capable of excision. In silico probing of C. difficile genome sequences with recombinase gene fragments identified new putative conjugative and mobilisable transposons related to the elements in strains 630 and R20291. CTn5-like elements were described occupying different insertion sites in different strains, CTn1-like elements that have lost the ability to excise in some ribotype 027 strains were described and one strain was shown to contain CTn5-like and CTn7-like elements arranged in tandem. Additionally, using bioinformatics, we updated previous gene annotations and predicted novel functions for the accessory gene products on these new elements. R20291Conclusions
The genomes of the C. difficile strains examined contain highly related CTns suggesting recent horizontal gene transfer. Several elements were capable of excision and conjugative transfer. The presence of antibiotic resistance genes and genes predicted to promote adaptation to the intestinal environment suggests that CTns play a role in the interaction of C. difficile with its human host. 相似文献8.
9.
Understanding the molecular basis of Clostridium difficile infection is a prerequisite to the development of effective countermeasures. Although there are methods for constructing gene-specific mutants of C. difficile, currently there is no effective method for generating libraries of random mutants. In this study, we developed a novel mariner-based transposon system for in vivo random mutagenesis of C. difficile , the BI/NAP1/027 epidemic strain at the center of the C. difficile outbreaks in Stoke Mandeville, United Kingdom, in 2003 to 2004 and 2004 to 2005. Transposition occurred at a frequency of 4.5 (±0.4) × 10−4 per cell to give stable insertions at random genomic loci, which were defined only by the nucleotide sequence TA. Furthermore, mutants with just a single transposon insertion were generated in an overwhelming majority (98.3% in this study). Phenotypic screening of a C. difficile R20291 random mutant library yielded a sporulation/germination-defective clone with an insertion in the germination-specific protease gene cspBA and an auxotroph with an insertion in the pyrimidine biosynthesis gene pyrB. These results validate our mariner-based transposon system for use in forward genetic studies of C. difficile.Clostridium difficile infection is widely recognized as the leading cause of health care-associated diarrhea in North America and Europe. Infection usually follows antibiotic treatment, which disrupts the native gastrointestinal microflora and thus allows C. difficile to proliferate. The emergence of so-called “epidemic” or “hypervirulent” strains of C. difficile over the last 5 to 10 years has compounded an already serious problem. Classed as BI/NAP1/027, these epidemic strains are believed to cause a more severe disease and lead to increased mortality and relapse rates ( R2029111, 20, 24).Understanding the genetic and molecular basis of C. difficile infection will be a crucial step in the development of effective countermeasures. Methods for directed gene inactivation in C. difficile have recently been described (7, 21). This has opened the way for reverse genetic studies, in which the exact role of a specific gene, hypothesized to be important in a given phenotype, can be elucidated experimentally. By way of contrast, forward genetic studies aim to identify the genetic basis of a particular phenotype without making any assumptions about the genes involved. In forward genetic studies, transposons are often used to generate libraries of random insertion mutants. Libraries are then screened to identify mutants that are defective in a particular phenotype. Identification of the gene or genes which have been inactivated by transposon insertion then implicates them as having a role in that particular phenotype. Recently, just such an approach was used to identify a novel toxin-regulatory locus in Clostridium perfringens (29). This study elegantly demonstrated the power of forward genetic studies in bacterial pathogens.A number of transposon mutagenesis systems have been described for Gram-positive bacteria (2, 3, 15, 16, 29, 32). Two different systems have recently been developed for use in C. perfringens (15, 29). Both are in vitro mutagenesis systems which rely on being able to transform the recipient organism. As such, they are not suitable for use in C. difficile because in the laboratory at present, recombinant DNA can be transferred into C. difficile only via conjugation. The conjugative transposons Tn916 and Tn5397 have been studied in C. difficile, but both have been found either to have a strong target site preference or to yield multiple insertions in individual clones (9, 30). Therefore, neither is well suited to generating libraries of random C. difficile mutants.We reasoned that a mariner-based transposon mutagenesis system would be an effective tool for generating libraries of random C. difficile mutants. The mariner-transposable element Himar1 has been shown to insert randomly into the genomes of many bacterial species (3, 6, 16, 17, 32). The cognate Himar1 transposase is the only factor required for transposition, which occurs via a cut-and-paste mechanism (13, 14). The transposon itself is defined by inverted terminal repeats (ITRs) at either end and inserts into a TA target site. This is highly appropriate for an organism with a low-GC content such as C. difficile. In this study, we have developed a novel mariner-based transposon system for in vivo random mutagenesis of C. difficile. Moreover, we have demonstrated the system in C. difficile , the BI/NAP1/027 epidemic strain at the center of the C. difficile outbreaks in Stoke Mandeville, United Kingdom, in 2003 to 2004 and 2004 to 2005. This new genetic tool opens the way for forward genetic studies of C. difficile. R20291相似文献
10.
Yen Kuan Ng Muhammad Ehsaan Sheryl Philip Mark M. Collery Clare Janoir Anne Collignon Stephen T. Cartman Nigel P. Minton 《PloS one》2013,8(2)
Sophisticated genetic tools to modify essential biological processes at the molecular level are pivotal in elucidating the molecular pathogenesis of Clostridium difficile, a major cause of healthcare associated disease. Here we have developed an efficient procedure for making precise alterations to the C. difficile genome by pyrE-based allelic exchange. The robustness and reliability of the method was demonstrated through the creation of in-frame deletions in three genes (spo0A, cwp84, and mtlD) in the non-epidemic strain 630Δerm and two genes (spo0A and cwp84) in the epidemic PCR Ribotype 027 strain, . The system is reliant on the initial creation of a pyrE deletion mutant, using Allele Coupled Exchange (ACE), that is auxotrophic for uracil and resistant to fluoroorotic acid (FOA). This enables the subsequent modification of target genes by allelic exchange using a heterologous pyrE allele from Clostridium sporogenes as a counter-/negative-selection marker in the presence of FOA. Following modification of the target gene, the strain created is rapidly returned to uracil prototrophy using ACE, allowing mutant phenotypes to be characterised in a PyrE proficient background. Crucially, wild-type copies of the inactivated gene may be introduced into the genome using ACE concomitant with correction of the pyrE allele. This allows complementation studies to be undertaken at an appropriate gene dosage, as opposed to the use of multicopy autonomous plasmids. The rapidity of the ‘correction’ method (5–7 days) makes pyrE
− strains attractive hosts for mutagenesis studies. R20291相似文献
11.
Clostridium difficile is the major cause of infectious diarrhea and a major burden to health care services. The ability of this organism to form endospores plays a pivotal role in infection and disease transmission. Spores are highly resistant to many forms of disinfection and thus are able to persist on hospital surfaces and disseminate infection. In order to cause disease, the spores must germinate and the organism must grow vegetatively. Spore germination in Bacillus is well understood, and genes important for this process have recently been identified in Clostridium perfringens; however, little is known about C. difficile. Apparent homologues of the spore cortex lytic enzyme genes cwlJ and sleB (Bacillus subtilis) and sleC (C. perfringens) are present in the C. difficile genome, and we describe inactivation of these homologues in C. difficile 630Δerm and a B1/NAP1/027 clinical isolate. Spores of a sleC mutant were unable to form colonies when germination was induced with taurocholate, although decoated sleC spores formed the same number of heat-resistant colonies as the parental control, even in the absence of germinants. This suggests that sleC is absolutely required for conversion of spores to vegetative cells, in contrast to CD3563 (a cwlJ/sleB homologue), inactivation of which had no effect on germination and outgrowth of C. difficile spores under the same conditions. The B1/NAP1/027 strain was found to sporulate more slowly and produce fewer spores than 630Δerm. Furthermore, fewer R20291 spores germinated, indicating that there are differences in both sporulation and germination between these epidemic and nonepidemic C. difficile isolates.The Gram-positive anaerobe Clostridium difficile causes diarrheal diseases ranging from asymptomatic carriage to a fulminant, relapsing, and potentially fatal colitis ( R202918, 30). This organism is resistant to various broad-spectrum antibiotics and capitalizes on disruption of the normal intestinal flora to colonize and cause disease symptoms through the action of toxins A and B (16, 40). While these toxins are the principal virulence factors, the ability of the organism to produce endospores is necessary for disease transmission.Clostridial spores are extremely resistant to all kinds of chemical and physical agents and provide the mechanism by which C. difficile can evade the potentially fatal consequences of exposure to heat, oxygen, alcohol, and certain disinfectants (35). Thus, the spores shed in fecal matter are very difficult to eradicate and can persist on contaminated surfaces in health care facilities for extended periods of time (35). This leads to infection or reinfection of cohabitating individuals through inadvertent ingestion of infected material (10, 32). Once in the anaerobic environment of the gut, spores presumably germinate to form toxin-producing vegetative cells and, in susceptible individuals, diarrheal disease.Spore germination is defined as the events that result in the irreversible loss of spore characteristics. However, current mechanistic knowledge of the germination process is based principally on data derived from studying Bacillus subtilis. Little is known about spore germination in clostridia and, in particular, in C. difficile. Germination is initiated when the bacterial spore senses specific effectors, termed germinants. These effectors can include nutrients, cationic surfactants, peptidoglycan, and a 1:1 chelate of pyridine-2,6-dicarboxylic acid (dipicolinic acid) and Ca2+ (CaDPA) (23, 34, 36). Spores of B. subtilis can germinate in response to nutrients through the participation of three sensory receptors located in the spore inner membrane, GerA, GerB, and GerK (23). After activation, the events include the release of monovalent cations (H+, K+, and Na+) and CaDPA (accounting for approximately 10% of the spore dry weight) (36). The third major step in germination involves hydrolysis of the spore peptidoglycan (PG) cortex. It is during this hydrolysis that the previously low water content of the spore is restored to the water content of a normal vegetative cell and the core is able to expand, which in turn allows enzyme activity, metabolism, and spore outgrowth (36).CwlJ and SleB are two specific spore cortex-lytic enzymes (SCLEs) involved in Bacillus cortex hydrolysis, which break down PG containing muramic-δ-lactam (28). SleB has been shown to localize in both the inner and outer layers of B. subtilis spores through interaction of the enzyme peptidoglycan-binding motif and the δ-lactam structure of the cortex (7, 19) and in association with YpeB, which is required for sleB expression during sporulation (4, 7). SleB is a lytic transglycosylase muramidase, but so far its mode of activation is unknown (21). CwlJ is localized to the spore coat during sporulation (3) and is required for CaDPA-induced germination in B. subtilis. Activation can be due to either CaDPA released from the spore core at the onset of germination or exogenous CaDPA (22). Neither enzyme is individually essential for complete cortex hydrolysis during nutrient germination, although inactivation of both cwlJ and sleB in B. subtilis results in a spore unable to complete this process (15). The role of SleL has recently been studied in Bacillus anthracis. Mutants unable to produce this enzyme are still able to germinate, but the process is retarded (18).The SCLEs of Clostridium are less well studied than those of Bacillus. The SCLEs SleC (20) and SleM (6) have been identified in Clostridium perfringens, and a recent study demonstrated that SleC is required during germination for complete cortex hydrolysis (26). Although SleM can degrade spore cortex peptidoglycan and inactivation of both sleC and sleM decreased the ability of spores to germinate more than inactivation of sleC alone did, SleM was not essential (26). It has also been shown that the germination-specific serine protease CspB is essential for cortex hydrolysis and converts the inactive pro-SleC found in dormant spores to an active enzyme (24). So far, there has been no detailed study of any gene responsible for spore germination in C. difficile, although genes showing homology to cwlJ and sleB of B. subtilis (CD3563) and sleC of C. perfringens (CD0551) have now been identified in the C. difficile 630 genome (33).With germinant receptors in C. difficile yet to be identified, the mechanism by which the spores sense a suitable environment for germination is unclear. Recent studies have suggested that this process may involve the interaction of C. difficile with bile. Taurocholate has been shown to enhance recovery of C. difficile spores in nutrient-rich medium (42), and it has been proposed that glycine and taurocholate act as cogerminants (38), while chenodeoxycholate inhibits C. difficile spore germination (39).The emergence of C. difficile B1/NAP1/027 strains has increased the burden on health care services worldwide. Such strains have been shown to produce higher levels of toxin in the laboratory than many other types of strains (41), although the mechanism behind this production is not fully understood. However, while the observed higher levels of toxin production is doubtless important, perhaps the recent attention given to B1/NAP1/027 strains has focused too much on toxins. As spores represent the infectious stage of C. difficile, processes such as spore germination may also contribute to the greater virulence of these strains. In this study we evaluated the sporulation and germination efficiencies of an “epidemic” B1/NAP1/027 C. difficile strain (, isolated from the Stoke Mandeville outbreak in 2004 and 2005) and the “nonepidemic” strain 630Δerm ( R2029114). We then constructed strains with mutations in CD3563 (a cwlJ/sleB homologue) and a sleC homologue to analyze the role of these genes in the germination of C. difficile spores. 相似文献
12.
Shuanglin Peng Yujin Gao Sirong Shi Dan Zhao Huayue Cao Ting Fu Xiaoxiao Cai Jingang Xiao 《Cell proliferation》2022,55(1)
ObjectivesBone tissue engineering based on adipose‐derived stem cells (ASCs) is expected to become a new treatment for diabetic osteoporosis (DOP) patients with bone defects. However, compared with control ASCs (CON‐ASCs), osteogenic potential of DOP‐ASCs is decreased, which increased the difficulty of bone reconstruction in DOP patients. Moreover, the cause of the poor osteogenesis of ASCs in a hyperglycemic microenvironment has not been elucidated. Therefore, this study explored the molecular mechanism of the decline in the osteogenic potential of DOP‐ASCs from the perspective of epigenetics to provide a possible therapeutic target for bone repair in DOP patients with bone defects.Materials and methodsAn animal model of DOP was established in mice. CON‐ASCs and DOP‐ASCs were isolated from CON and DOP mice, respectively. small interfering RNA (SiRNA) and an AK137033 overexpression plasmid were used to regulate the expression of AK137033 in CON‐ASCs and DOP‐ASCs in vitro. Lentiviruses that carried shRNA‐ AK137033 or AK137033 cDNA were used to knockdown or overexpress AK137033, respectively, in CON‐ASCs and DOP‐ASCs in vivo. Hematoxylin and eosin (H&E), Masson''s, alizarin red, and alkaline phosphatase (ALP) staining, micro‐computed tomography (Micro‐CT), flow cytometry, qPCR, western blotting, immunofluorescence, and bisulfite‐specific PCR (BSP) were used to analyze the functional changes of ASCs.ResultsThe DOP mouse model was established successfully. Compared with CON‐ASCs, AK137033 expression, the DNA methylation level of the sFrp2 promoter region, Wnt signaling pathway markers, and the osteogenic differentiation potential were decreased in DOP‐ASCs. In vitro experiments showed that AK137033 silencing inhibited the Wnt signaling pathway and osteogenic ability of CON‐ASCs by reducing the DNA methylation level in the sFrp2 promoter region. Additionally, overexpression of AK137033 in DOP‐ASCs rescued these changes caused by DOP. Moreover, the same results were obtained in vivo.ConclusionsLncRNA‐ AK137033 inhibits the osteogenic potential of DOP‐ASCs by regulating the Wnt signaling pathway via modulating the DNA methylation level in the sFrp2 promoter region. This study provides an important reference to find new targets for the treatment of bone defects in DOP patients. AK137033相似文献
13.
Senbagam Duraisamy Fazal Husain Senthilkumar Balakrishnan Aswathy Sathyan Prabhu Subramani Prahalathan Chidambaram Selvaraj Arokiyaraj Wahidah H. Al-Qahtani Jothiramalingam Rajabathar Anbarasu Kumarasamy 《Current issues in molecular biology》2022,44(2):731
Breast milk is the combination of bioactive compounds and microflora that promote newborn’s proper growth, gut flora, and immunity. Thus, it is always considered the perfect food for newborns. Amongst their bioactives, probiotic communities—especially lactic acid bacteria (LAB)—are characterized from breast milk over the first month of parturition. In this study, seven LAB were characterized phenotypically and genotypically as Levilactobacillus brevis BDUMBT08 (), L. gastricus BDUMBT09 ( MT673657), L. paracasei BDUMBT10 ( MT774596), L. brevis BDUMBT11 ( MT775430), L. casei BDUMBT12 ( MW785062), L. casei BDUMBT13 ( MW785063), and Brevibacillus brevis M2403 ( MW785178) from human breast milk. Their tolerance to lysozyme, acid, bile, gastric juice, pancreatic juice, and NaCl and potential for mucoadhesion, auto-aggregation, and co-aggregation with pathogens are of great prominence in forecasting their gut colonizing ability. They proved their safety aspects as they were negative for virulence determinants such as hemolysis and biofilm production. Antibiogram of LAB showed their sensitivity to more than 90% of the antibiotics tested. Amongst seven LAB, three isolates (L. brevis BDUMBT08 and BDUMBT11, and L. gatricus BDUMBT09) proved their bacteriocin producing propensity. Although the seven LAB isolates differed in their behavior, their substantial probiotic properties with safety could be taken as promising probiotics for further studies to prove their in vivo effects, such as health benefits, in humans. MK371781相似文献
14.
15.
Background
There is large variability among lung squamous cell carcinoma patients in response to treatment with cisplatin based chemotherapy. LncRNA is potentially a new type of predictive marker that can identify subgroups of patients who benefit from chemotherapy and it will have great value for treatment guidance.Methods
Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of .3-003 was assessed in another 60 tumor samples. AC006050Results
Compared with the PD samples, 953 lncRNAs were consistently upregulated and 749 lncRNAs were downregulated consistently among the differentially expressed lncRNAs in PR samples (Fold Change≥2.0-fold, p <0.05). Pathway analyses showed that some classical pathways, including “Nucleotide excision repair,” that participated in cisplatin chemo response were differentially expressed between PR and PD samples. Coding-non-coding gene co-expression network identified many lncRNAs, such as lncRNA .3-003, that potentially played a key role in chemo response. The expression of lncRNA AC006050.3-003 was significantly lower in PR samples compared to the PD samples in another 60 lung squamous cell carcinoma patients. Receiver operating characteristic curve analysis revealed that lncRNA AC006050.3-003 was a valuable biomarker for differentiating PR patients from PD patients with an area under the curve of 0.887 (95% confidence interval 0.779, 0.954). AC006050Conclusions
LncRNAs seem to be involved in cisplatin-based chemo response and may serve as biomarkers for treatment response and candidates for therapy targets in lung squamous cell carcinoma. 相似文献16.
Kristina Martinez Shruthi Shyamasundar Arion Kennedy Chia Chi Chuang Angel Marsh Jennifer Kincaid Tanya Reid Michael McIntosh 《Journal of lipid research》2013,54(3):662-670
Diacylglycerol kinases (DGK) convert diacylglycerol to phosphatidic acid, which has been reported to stimulate calcium release from the endoplasmic reticulum. Based on our published data showing that trans-10, cis-12 conjugated linoleic acid (t10,c12 CLA)-mediated intracellular calcium accumulation is linked to inflammation and insulin resistance, we hypothesized that inhibiting DGKs with would prevent t10,c12 CLA-mediated inflammatory signaling and insulin resistance in human adipocytes. Consistent with our hypothesis, R59022 attenuated t10,c12 CLA-mediated i) increased gene expression and protein secretion of interleukin (IL)-8, IL-6, and monocyte chemoattractant protein-1 (MCP-1); ii) increased activation of extracellular signal-related kinase (ERK), cJun-NH2-terminal kinase (JNK), and cJun; iii) increased intracellular calcium levels; iv) suppressed mRNA or protein levels of peroxisome proliferator activated receptor γ, adiponectin, and insulin-dependent glucose transporter 4; and v) decreased fatty acid and glucose uptake and triglyceride content. DGKη was targeted for investigation based on our findings that i) DGKη was highly expressed in primary human adipocytes and time-dependently induced by t10,c12 CLA and that ii) t10,c12 CLA-induced DGKη expression was dose-dependently decreased with R59022. Small interfering RNA (siRNA) targeting DGKη decreased t10,c12 CLA-induced DGKη, IL-8, and MCP-1 gene expression, as well as activation of JNK and cJun. Taken together, these data suggest that DGKs mediate, in part, t10,c12 CLA-induced inflammatory signaling in primary human adipocytes. R59022相似文献
17.
18.
19.
20.
The purpose of this table is to provide the community with a citable record of publications of ongoing genome sequencing projects that have led to a publication in the scientific literature. While our goal is to make the list complete, there is no guarantee that we may have omitted one or more publications appearing in this time frame. Readers and authors who wish to have publications added to subsequent versions of this list are invited to provide the bibliographic data for such references to the SIGS editorial office.
Phylum Crenarchaeota
- Pyrobaculum strain 1860, sequence accession [ CP0030981]
Phylum Deinococcus-Thermus
- “Thermus sp.” Strain CCB_US3_UF1, sequence accession (chromosome), CP003126 (plasmid) [ CP0031272]
Phylum Proteobacteria
- “Achromobacter arsenitoxydans” SY8, sequence accession [ AGUF000000003]
- Acidovorax sp. Strain NO1, sequence accession [ AGTS000000004]
- Acinetobacter baumannii AB4857, sequence accession [ AHAG000000005]
- Acinetobacter baumannii AB5075, sequence accession [ AHAH000000005]
- Acinetobacter baumannii AB5256, sequence accession [ AHAI000000005]
- Acinetobacter baumannii AB5711, sequence accession [ AHAJ000000005]
- Aeromonas salmonicida, sequence accession [ AGVO000000006]
- Aggregatibacter actinomycetemcomitans RHAA1, sequence accession [ AHGR000000007]
- Agrobacterium tumefaciens 5A, sequence accession [ AGVZ000000008]
- Azoarcus sp. Strain KH32C, sequence accession , AP012304 [ AP0123059]
- Burkholderia sp. Strain YI23, sequence accession (Chromosome 1), CP003087 (Chromosome 2), CP003088 (Chromosome 3), CP003089 (plasmid BYI23_D), CP003090 (plasmid BYI23_E) CP003091 (plasmid BYI23_F) [ CP00309210]
- Brucella suis VBI22, sequence accession , CP003128 [ CP00312911]
- Comamonas testosteroni ATCC 11996, sequence accession [ AHIL0000000012]
- “Commensalibacter intestini” A911T, sequence accession [ AGFR0000000013]
- Edwardsiella ictaluri, sequence accession [ CP001600.114]
- Enterobacter cloacae subsp. dissolvens SDM, sequence accession [ AGSY0000000015]
- “Gluconobacter morbifer” G707T, sequence accession [ AGQV0000000016]
- Legionella dumoffii TEX-KL, sequence accession [ AGVT0000000017]
- Legionella dumoffii NY-23, sequence accession [ AGVU0000000017]
- Legionella pneumophila serogroup 12 Strain 570-CO-H, sequence accession [ CP00319218]
- Marinobacterium stanieri S30, sequence accession [ AFPL0000000019]
- “Marinobacter manganoxydans” MnI7-9, sequence accession [ CP001978 to CP00198020]
- Mesorhizobium alhagi CCNWXJ12-2T, sequence accession [ AHAM0000000021]
- Mesorhizobium amorphae, sequence accession [ AGSN0000000022]
- Methylomicrobium alcaliphilum 20Z, sequence accession and FO082060 [ FO08206123]
- Mitsuaria sp. Strain H24L5A, sequence accession [ CAFG01000001 to CAFG0100060724]
- Novosphingobium pentaromativorans US6-1, sequence accession [ AGFM0000000025]
- Pantoea ananatis B1-9, sequence accession [ CAEI01000001 to CAEI0100016926]
- Pantoea ananatis LMG 5342, sequence accession (chromosome), HE617160 (pPANA10) [ HE61716127]
- Pantoea ananatis Strain PA13, sequence accession and CP003085 [ CP00308628]
- Pseudomonas aeruginosa, sequence accession [ AFXI0000000029]
- Pseudomonas aeruginosa, sequence accession [ AFXJ0000000029]
- Pseudomonas aeruginosa, sequence accession [ AFXK0000000029]
- Pseudomonas chlororaphis GP72, sequence accession [ AHAY0100000030]
- Pseudomonas fluorescens F113, sequence accession [ CP00315031]
- Pseudomonas fluorescens Wayne 1R, sequence accession [ CADX01000001 to CADX0100009032]
- Pseudomonas fluorescens Wood1R, sequence accession to CAFF01000001 [ CAFF0100143732]
- Pseudomonas psychrotolerans L19, sequence accession [ AHBD0000000033]
- Pseudoalteromonas rubra ATCC 29570T, sequence accession [ AHCD0000000034]
- Pseudomonas stutzeri SDM-LAC, sequence accession [ AGSX0000000035]
- Pseudoxanthomonas spadix BD-a59, sequence accession [ CP00309336]
- Rickettsia slovaca, sequence accession [ CP00242837]
- Salmonella enterica serovar Pullorum RKS5078, sequence accession [ CP00304738]
- Sinorhizobium meliloti CCNWSX0020, sequence accession [ AGVV0000000039]
- Sphingobium sp. Strain SYK-6, sequence accession and AP012222 [ AP01222340]
- Sphingomonas sp. Strain PAMC 26605, sequence accession [ AHIS0000000041]
- Stenotrophomonas maltophilia RR-10, sequence accession [ AGRB0000000042]
- Strain HIMB30, sequence accession [ AGIG0000000043]
- Taylorella equigenitalis, sequence accession [ CP00305944]
- Vibrio campbellii DS40M4, sequence accession [ AGIE0000000045]
- Vibrio fischeri SR5, sequence accession [ AHIH0000000046]
- Yersinia enterocolitica, sequence accession [ AGQO0000000047]
Phylum Tenericutes
- Candidatus Mycoplasma haemominutum, sequence accession [ HE61325448]
- Mycoplasma haemocanis strain Illinois, sequence accession [ CP00319949]
- Mycoplasma iowae, sequence accession [ AGFP0000000050]
- Mycoplasma pneumoniae Type 2a Strain 309, sequence accession [ AP01230351]
Phylum Firmicutes
- Bacillus cereus F837/76, sequence accession (chromosome) CP003187 (pF837_55kb), CP003188 (pF837_10kb) [ CP00318952]
- Brevibacillus laterosporus Strain GI-9, sequence accession [ CAGD01000001 to CAGD0100006153]
- Clostridium sporogenes PA 3679, sequence accession [ AGAH0000000054]
- Enterococcus mundtii CRL1656, sequence accession [ AFWZ00000000.155]
- Geobacillus thermoleovorans CCB_US3_UF5, sequence accession [ CP00312556]
- Lactobacillus curvatus Strain CRL705, sequence accession [ AGBU0100000057]
- Lactobacillus rhamnosus ATCC 8530, sequence accession [ CP00309458]
- Lactobacillus rhamnosus R0011, sequence accession [ AGKC0000000059]
- Lactococcus garvieae TB25, sequence accession [ AGQX0100000060]
- Lactococcus garvieae LG9, sequence accession [ AGQY0100000060]
- Lactococcus lactis subsp. cremoris A76, sequence accession (chromosome), CP003132 (pQA505), CP003136 (PQA518), CP003135 (pQA549), CP003134 (pQA554) [ CP00313361]
- Leuconostoc citreum LBAE C10, sequence accession [ CAGE0000000062]
- Leuconostoc citreum LBAE C11, sequence accession [ CAGF0000000062]
- Leuconostoc citreum LBAE E16, sequence accession [ CAGG0000000062]
- Leuconostoc mesenteroides subsp. mesenteroides Strain J18, sequence accession [ CP00310163]
- Paenibacillus peoriae Strain KCTC 3763T, sequence accession [ AGFX0000000064]
- Pediococcus acidilactici MA18/5M, sequence accession [ AGKB0000000065]
- Pediococcus claussenii ATCC BAA-344T, sequence accession (chromosome), CP003137 (pPECL-1), CP003138 (pPECL-2), CP003139 (pPECL-3), CP003140 (pPECL-4), CP003141 (pPECL-5), CP003142 (pPECL-6), CP003143 (pPECL-7), CP003144 (pPECL-8) [ CP00314566]
- Staphylococcus aureus M013, sequence accession [ CP00316667]
- Staphylococcus aureus subsp. aureus TW20, sequence accession [ FN43359668]
- Weissella confusa LBAE C39-2, sequence accession [ CAGH0000000069]
Phylum Actinobacteria
- Corynebacterium casei, sequence accession [ CAFW01000001 to CAFW0100010670]
- Corynebacterium glutamicum, sequence accession [ AGQQ0000000071]
- Leucobacter chromiiresistens, sequence accession [ AGCW0000000072]
- Mycobacterium abscessus, sequence accession [ AGQU0000000073]
- Propionibacterium acnes ST9, sequence accession [ CP00319574]
- Propionibacterium acnes ST22, sequence accession [ CP00319674]
- Propionibacterium acnes ST27, sequence accession [ CP00319774]
- Saccharomonospora azurea SZMC 14600, sequence accession [ AHBX0000000075]
- Streptomyces sp. Strain TOR3209, sequence accession [ AGNH0000000076]
- Streptomyces sp. Strain W007, sequence accession [ AGSW0000000077]
Phylum Spirochaetes
- Borrelia valaisiana VS116, sequence accession (chromosome), ABCY02000001 (plasmid Ip17), CP001439 (Ip25), CP001437 (plasmid Ip 28-3), CP001440 (plasmid Ip28-8), CP001442 (Ip 36), CP001436 (plasmid Ip 54), CP001433 (plasmid cp9), CP001438 (plasmid cp26), CP001432 (plasmid cp32-5), CP001441 (plasmid cp32-7), CP001434 (plasmid cp32-10) [ CP00143578]
- “Borrelia bissettii” DN127, sequence accession (chromosome), CP002746 (plasmid Ip12), CP002756 (plasmid Ip25), CP002757 (plasmid 28-3), CP002758 (plasmid Ip 28-4), CP002759 (Ip28-7), CP002760 (plasmid Ip54), CP002761 (plasmid Ip56), CP002762 (plasmid cp9), CP002755 (plasmid cp26), CP002747 (plasmid cp32-3), CP002749 (plasmid cp32-4), CP002750 (plasmid 32-5), CP002751 (plasmid cp32-6), CP002752 (plasmid cp32-7), CP0027554 (plasmid cp32-9), CP002753 (plasmid cp32-11) [ CP00274878]
- Borrelia spielmanii A14S, sequence accession (chromosome), ABKB02000001 (plasmid Ip17), CP001468 (Ip28-3), CP001471 (plasmid Ip28-4), CP001470 (plasmid Ip28-2), CP001465 (plasmid Ip36), CP001466 (plasmid Ip38), CP001464 (plasmid Ip54), CP001469, ABKB02000016 (plasmid cp9), ABKB02000020 (plasmid cp26), CP001467 (plasmid cp32-3), ABKB02000026 (plasmid 32-5), ABKB02000031 (plasmid cp32-12), ABKB02000021 (unidentified) [ ABKB0200001478]
Non-Bacterial genomes
- Aspergillus flavus, sequence accession [ GSE3217779]
- Bacteriophage SPN3UB, sequence accession [ JQ28802180]
- Bamboo mitochondria, sequence accession [ JQ235166 to JQ23517981]
- Boea hygrometrica chloroplast, sequence accession [ JN10781182]
- Boea hygrometrica mitochondrial, sequence accession [ JN10781282]
- Canine Picornavirus, sequence accession [ JN83135683]
- Chandipura virus (CHPV) CIN0327, sequence accession [ GU212856.184]
- Chandipura virus (CHPV) CIN0451, sequence accession [ GU212857.184]
- Chandipura virus (CHPV) CIN0751, sequence accession [ GU212858.184]
- Chandipura virus (CHPV) CIN0755, sequence accession [ GU190711.184]
- Chinese Porcine Parvovirus Strain PPV2010, sequence accession [ JN87244885]
- Common midwife toad megavirus, sequence accession [ JQ23122286]
- Dengue Virus Serotype 4, sequence accession [ JN98381387]
- Duck Tembusu Virus, sequence accession [ JF27048088]
- Duck Tembusu Virus, sequence accession [ JQ31446488]
- Duck Tembusu Virus, sequence accession [ JQ31446588]
- Emiliania huxleyi Virus 202, sequence accession [ HQ63414589]
- Emiliania huxleyi Virus EhV-88, sequence accession [ JF97431089]
- Emiliania huxleyi EhV-201, sequence accession [ JF97431189]
- Emiliania huxleyi EhV-207, sequence accession [ JF97431789]
- Emiliania huxleyi EhV-208, sequence accession [ JF97431889]
- Glarea lozoyensis, sequence accession GUE00000000 [90]
- Nannochloropis gaditana, sequence accession [ AGNI0000000091]
- Oryza sativa cv., sequence accession DRA000499 [92]
- Partetravirus, sequence accession [ JN99026993]
- Porcine Bocavirus PBoV5, sequence accession [ JN83165194]
- Porcine epidemic diarrhea virus, sequence accession [ JQ28290995]
- Pseudomonas aeruginosa lytic bacteriophage PA1Ø, sequence accession [ HM62408096]
- Pseudomonas fluorescens phage OBP, sequence accesssion [ JN62716097]
- RNA Virus from Avocado, sequence accession [ JN88041498]
- Salmonella enterica Serovar Typhimurium Bacteriophage SPN1S, sequence accession [ JN39118099]
- Schistosoma haematobium, sequence accession PRJNA78265 [100]
- Schistosoma mansoni, sequence accession [ ERP00038101]
- Stenopirates sp., sequence accession [ JN100019102]
- T7-Like Virus, sequence accession [ JN651747103]
- Vibrio harveyi siphophage VHS1, sequence accession [ JF713456104]
- Tyrolean ice man, sequence accession ERP001144 [105]